Identification of EP300 as a Key Gene Involved in Antipsychotic-Induced Metabolic Dysregulation Based on Integrative Bioinformatics Analysis of Multi-Tissue Gene Expression Data.

Saved in:

Bibliographic Details
Title:	Identification of EP300 as a Key Gene Involved in Antipsychotic-Induced Metabolic Dysregulation Based on Integrative Bioinformatics Analysis of Multi-Tissue Gene Expression Data.
Authors:	Martínez-Pinteño A; Department of Basic Clinical Practice, Pharmacology Unit, University of Barcelona, Barcelona, Spain., Gassó P; Department of Basic Clinical Practice, Pharmacology Unit, University of Barcelona, Barcelona, Spain.; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain., Prohens L; Department of Basic Clinical Practice, Pharmacology Unit, University of Barcelona, Barcelona, Spain., Segura AG; Department of Basic Clinical Practice, Pharmacology Unit, University of Barcelona, Barcelona, Spain., Parellada M; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain.; Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IiSGM, Madrid, Spain., Saiz-Ruiz J; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain.; Department of Psychiatry, Hospital Universitario Ramón y Cajal, IRYCIS, Universidad de Alcalá, Madrid, Spain., Cuesta MJ; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain.; Department of Psychiatry, Complejo Hospitalario de Navarra, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain., Bernardo M; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain.; Barcelona Clínic Schizophrenia Unit, Hospital Clínic de Barcelona, Barcelona, Spain.; Department of Medicine, University of Barcelona, Barcelona, Spain., Lafuente A; Department of Basic Clinical Practice, Pharmacology Unit, University of Barcelona, Barcelona, Spain.; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain., Mas S; Department of Basic Clinical Practice, Pharmacology Unit, University of Barcelona, Barcelona, Spain.; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain., Rodríguez N; Department of Basic Clinical Practice, Pharmacology Unit, University of Barcelona, Barcelona, Spain.
Source:	Frontiers in pharmacology [Front Pharmacol] 2021 Aug 13; Vol. 12, pp. 729474. Date of Electronic Publication: 2021 Aug 13 (Print Publication: 2021).
Publication Type:	Journal Article
Journal Info:	Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	1663-9812
DOI:	10.3389/fphar.2021.729474